MALDI mass spectrometry imaging analysis of pituitary adenomas for near-real-time tumor delineation

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 32, 2015, Pages 9978-9983

  Calligaris, David ^a   Feldman, Daniel R ^a   Norton, Isaiah ^a   Olubiyi, Olutayo ^a   Changelian, Armen N ^a   Machaidze, Revaz ^a   Vestal, Matthew L ^a   Laws, Edward R ^a   Dunn, Ian F ^a   Santagata, Sandro ^a,b   Agar, Nathalie Y R ^a,b   Meinwald, Jerrold ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c Cornell University ^*  (United States)

Author keywords

In source decay; Intrasurgical diagnosis; Mass spectrometry imaging; Molecular pathology; Pituitary

Indexed keywords

BETA ENDORPHIN; CORTICOTROPIN; FOLLITROPIN; GROWTH HORMONE; LUTEINIZING HORMONE; NEUROPHYSIN; NEUROPHYSIN 2; PROLACTIN; THYROTROPIN; UNCLASSIFIED DRUG; VASOPRESSIN; TUMOR PROTEIN;

ACTH SECRETING ADENOMA; ARTICLE; CLINICAL ARTICLE; CRYSTALLIZATION; GROWTH HORMONE SECRETING ADENOMA; HISTOPATHOLOGY; HORMONE RELEASE; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; TISSUE CHARACTERIZATION; TUMOR LOCALIZATION; COMPUTER SYSTEM; HYPOPHYSIS; METABOLISM; PATHOLOGY; PITUITARY NEOPLASMS; PRINCIPAL COMPONENT ANALYSIS; PROCEDURES; REPRODUCIBILITY; THREE DIMENSIONAL IMAGING;

COMPUTER SYSTEMS; HUMANS; IMAGING, THREE-DIMENSIONAL; NEOPLASM PROTEINS; PITUITARY GLAND; PITUITARY NEOPLASMS; PRINCIPAL COMPONENT ANALYSIS; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84938920486     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1423101112     Document Type: Article

References (57)

1. Ezzat S, et al. (2004) The prevalence of pituitary adenomas: A systematic review. Cancer 101(3): 613-619.
2. Ezzat S, Asa SL (2006) Mechanisms of disease: The pathogenesis of pituitary tumors. Nat Clin Pract Endocrinol Metab 2(4): 220-230.
3. Fernandez A, Karavitaki N, Wass JA (2010) Prevalence of pituitary adenomas: A community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf) 72(3): 377-382.
4. Pisaneschi M, Kapoor G (2005) Imaging the sella and parasellar region. Neuroimaging Clin N Am 15(1): 203-219.
5. Elamin MB, et al. (2008) Accuracy of diagnostic tests for Cushing's syndrome: A systematic review and metaanalyses. J Clin Endocrinol Metab 93(5): 1553-1562.
6. Melmed S, et al.; Endocrine Society (2011) Diagnosis and treatment of hyperprolactinemia: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96(2): 273-288.
7. Nieman LK, et al. (2008) The diagnosis of Cushing's syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 93(5): 1526-1540.
8. Freda PU, et al.; Endocrine Society (2011) Pituitary incidentaloma: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 96(4): 894-904.
9. Arafah BM, Prunty D, Ybarra J, Hlavin ML, Selman WR (2000) The dominant role of increased intrasellar pressure in the pathogenesis of hypopituitarism, hyperprolactinemia, and headaches in patients with pituitary adenomas. J Clin Endocrinol Metab 85(5): 1789-1793.
10. Locatelli M, et al. (2013) The trans-sphenoidal resection of pituitary adenomas in elderly patients and surgical risk. Pituitary 16(2): 146-151.
11. Hardy J (1962) [Excision of pituitary adenomas by trans-sphenoidal approach]. Union Med Can 91: 933-945.
12. Komotar RJ, Starke RM, Raper DM, Anand VK, Schwartz TH (2012) Endoscopic endonasal compared with microscopic transsphenoidal and open transcranial resection of giant pituitary adenomas. Pituitary 15(2): 150-159.
13. Berkmann S, et al. (2011) Intraoperative magnetic resonance imaging and early prognosis for vision after transsphenoidal surgery for sellar lesions. J Neurosurg 115(3): 518-527.
14. Litvack ZN, Zada G, Laws ER, Jr (2012) Indocyanine green fluorescence endoscopy for visual differentiation of pituitary tumor from surrounding structures. J Neurosurg 116(5): 935-941.
15. Scheithauer B, Horvath E, Lloyd R, Kovacs K (2001) Pathology of Pituitary Adenomas and Pituitary Hyperplasia. Diagnosis and Management of Pituitary Tumors, eds Thapar K, Kovacs K, Scheithauer B, Lloyd R (Humana, New York), pp 91-154.
16. Bicknell AB (2008) The tissue-specific processing of pro-opiomelanocortin. J Neuroendocrinol 20(6): 692-699.
17. Thomas A, et al. (2013) Histology-driven data mining of lipid signatures from multiple imaging mass spectrometry analyses: Application to human colorectal cancer liver metastasis biopsies. Anal Chem 85(5): 2860-2866.
18. Cimino J, et al. (2013) Towards lipidomics of low-abundant species for exploring tumor heterogeneity guided by high-resolution mass spectrometry imaging. Int J Mol Sci 14(12): 24560-24580.
19. Caprioli RM, Farmer TB, Gile J (1997) Molecular imaging of biological samples: Localization of peptides and proteins using MALDI-TOF MS. Anal Chem 69(23): 4751-4760.
20. Wang HY, Wu HW, Tsai PJ, Liu CB (2012) MALDI-mass spectrometry imaging of desalted rat brain sections reveals ischemia-mediated changes of lipids. Anal Bioanal Chem 404(1): 113-124.
21. Balluff B, et al. (2011) MALDI imaging identifies prognostic seven-protein signature of novel tissue markers in intestinal-type gastric cancer. Am J Pathol 179(6): 2720-2729.
22. Elsner M, et al. (2012) MALDI imaging mass spectrometry reveals COX7A2, TAGLN2 and S100-A10 as novel prognostic markers in Barrett's adenocarcinoma. J Proteomics 75(15): 4693-4704.
23. Grobe N, Elased KM, Cool DR, Morris M (2012) Mass spectrometry for the molecular imaging of angiotensin metabolism in kidney. Am J Physiol Endocrinol Metab 302(8): E1016-E1024.
24. Cerruti CD, Benabdellah F, Laprévote O, Touboul D, Brunelle A (2012) MALDI imaging and structural analysis of rat brain lipid negative ions with 9-aminoacridine matrix. Anal Chem 84(5): 2164-2171.
25. Calligaris D, et al. (2014) Application of desorption electrospray ionization mass spectrometry imaging in breast cancer margin analysis. Proc Natl Acad Sci USA 111(42): 15184-15189.
26. Santagata S, et al. (2014) Intraoperative mass spectrometry mapping of an oncometabolite to guide brain tumor surgery. Proc Natl Acad Sci USA 111(30): 11121-11126.
27. Eberlin LS, et al. (2013) Ambient mass spectrometry for the intraoperative molecular diagnosis of human brain tumors. Proc Natl Acad Sci USA 110(5): 1611-1616.
28. Calligaris D, et al. (2013) Mass spectrometry imaging as a tool for surgical decisionmaking. J Mass Spectrom 48(11): 1178-1187.
29. Schöne C, Höfler H, Walch A (2013) MALDI imaging mass spectrometry in cancer research: Combining proteomic profiling and histological evaluation. Clin Biochem 46(6): 539-545.
30. Bateson H, Saleem S, Loadman PM, Sutton CW (2011) Use of matrix-assisted laser desorption/ionisation mass spectrometry in cancer research. J Pharmacol Toxicol Methods 64(3): 197-206.
31. McDonnell LA, Heeren RM, Andrén PE, Stoeckli M, Corthals GL (2012) Going forward: Increasing the accessibility of imaging mass spectrometry. J Proteomics 75(16): 5113-5121.
32. Dihazi H, et al. (2013) Mass spectrometry imaging: Linking molecule profiles to tissue spatial distribution. Expert Rev Proteomics 10(1): 17-20.
33. Yang J, Caprioli RM (2011) Matrix sublimation/recrystallization for imaging proteins by mass spectrometry at high spatial resolution. Anal Chem 83(14): 5728-5734.
34. Mohr E, Hillers M, Ivell R, Haulica ID, Richter D (1985) Expression of the vasopressin and oxytocin genes in human hypothalami. FEBS Lett 193(1): 12-16.
35. Kazmierkiewicz R, Czaplewski C, Ciarkowski J (1997) Elucidation of neurophysin/bioligand interactions from molecular modeling. Acta Biochim Pol 44(3): 453-466.
36. Suckau D, Resemann A (2003) T3-sequencing: Targeted characterization of the N- and C-termini of undigested proteins by mass spectrometry. Anal Chem 75(21): 5817-5824.
37. Suckau D, Resemann A (2009) MALDI Top-Down sequencing: Calling N- and C-terminal protein sequences with high confidence and speed. J Biomol Tech 20(5): 258-262.
38. Calligaris D, et al. (2010) MALDI in-source decay of high mass protein isoforms: Application to alpha- and beta-tubulin variants. Anal Chem 82(14): 6176-6184.
39. Menger RF, et al. (2012) MALDI mass spectrometric imaging of cardiac tissue following myocardial infarction in a rat coronary artery ligation model. Anal Chem 84(2): 1117-1125.
40. Reiber DC, Brown RS, Weinberger S, Kenny J, Bailey J (1998) Unknown peptide sequencing using matrix-assisted laser desorption/ionization and in-source decay. Anal Chem 70(6): 1214-1222.
41. Asakawa D, TakayamaM(2011) Specific cleavage at peptide backbone Ca-C and CO-N bonds during matrix-assisted laser desorption/ionization in-source decay mass spectrometry with 5-nitrosalicylic acid as the matrix. Rapid Commun Mass Spectrom 25(17): 2379-2383.
42. Smargiasso N, Quinton L, De Pauw E (2012) 2-Aminobenzamide and 2-aminobenzoic acid as new MALDI matrices inducing radical mediated in-source decay of peptides and proteins. J Am Soc Mass Spectrom 23(3): 469-474.
43. Asakawa D, Takayama M (2011) Ca-C bond cleavage of the peptide backbone in MALDI in-source decay using salicylic acid derivative matrices. J Am Soc Mass Spectrom 22(7): 1224-1233.
44. Demeure K, Quinton L, Gabelica V, De Pauw E (2007) Rational selection of the optimum MALDI matrix for top-down proteomics by in-source decay. Anal Chem 79(22): 8678-8685.
45. Sakakura M, Takayama M (2010) In-source decay and fragmentation characteristics of peptides using 5-aminosalicylic acid as a matrix in matrix-assisted laser desorption/ionization mass spectrometry. J Am Soc Mass Spectrom 21(6): 979-988.
46. Sellami L, et al. (2012) In-source decay and pseudo tandem mass spectrometry fragmentation processes of entire high mass proteins on a hybrid vacuum matrix-assisted laser desorption ionization-quadrupole ion-trap time-of-flight mass spectrometer. Anal Chem 84(12): 5180-5185.
47. Quinton L, et al. (2007) New method for characterizing highly disulfide-bridged peptides in complex mixtures: Application to toxin identification from crude venoms. J Proteome Res 6(8): 3216-3223.
48. Debois D, Bertrand V, Quinton L, De Pauw-Gillet MC, De Pauw E (2010) MALDI-in source decay applied to mass spectrometry imaging: A new tool for protein identification. Anal Chem 82(10): 4036-4045.
49. Ait-Belkacem R, et al. (2014) MALDI imaging and in-source decay for top-down characterization of glioblastoma. Proteomics 14(10): 1290-1301.
50. Calligaris D, et al. (2013) Selected protein monitoring in histological sections by targeted MALDI-FTICR in-source decay imaging. Anal Chem 85(4): 2117-2126.
51. Bonnel D, et al. (2011) Multivariate analyses for biomarkers hunting and validation through on-tissue bottom-up or in-source decay in MALDI-MSI: Application to prostate cancer. Anal Bioanal Chem 401(1): 149-165.
52. Lewis UJ, Sinha YN, Lewis GP (2000) Structure and properties of members of the hGH family: A review. Endocr J 47(Suppl): S1-S8.
53. Suckau D, et al. (2003) A novel MALDI LIFT-TOF/TOF mass spectrometer for proteomics. Anal Bioanal Chem 376(7): 952-965.
54. Schnaible V, et al. (2002) Screening for disulfide bonds in proteins by MALDI in-source decay and LIFT-TOF/TOF-MS. Anal Chem 74(19): 4980-4988.
55. Takayama M, Tsugita A (2000) Sequence information of peptides and proteins with in-source decay in matrix assisted laser desorption/ionization-time of flight-mass spectrometry. Electrophoresis 21(9): 1670-1677.
56. Osamura RY, et al. (2008) Pathology of the human pituitary adenomas. Histochem Cell Biol 130(3): 495-507.
57. Laws E, Ezzat S, Asa S, Rio L (2013) Pituitary Disorders: Diagnosis and Management (John Wiley & Sons, Malden, MA).